Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections.
Open accessThe DOI matches its Crossref record; 695 of the 697 references it cites were found in a registry or an index.
Abstract
Background: The Infectious Diseases Society of America is committed to providing up-to-date guidance on the treatment of antimicrobial-resistant infections. This guidance document focuses on infections caused by extended-spectrum β-lactamase–producing Enterobacterales, AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa with difficult-to-treat resistance, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia. This updated document replaces previous versions of the guidance document. Methods: A panel of 6 infectious diseases specialists with expertise in managing antimicrobial-resistant infections formulated questions about the treatment of infections caused by extended-spectrum β-lactamase-producing Enterobacterales, AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa with difficult-to-treat resistance, carbapenem-resistant Acinetobacter baumannii, and S. maltophilia. Because of differences in the epidemiology of resistance and availability of specific anti-infectives internationally, this document focuses on the treatment of infections in the United States. Results: Preferred and alternative suggested treatment approaches are provided with accompanying rationales, assuming the causative organism has been identified and antibiotic susceptibility results are known. Approaches to empiric treatment, transitioning to oral therapy, duration of therapy, and other management considerations are also discussed briefly. Suggested approaches apply for both adult and pediatric populations, although suggested antibiotic dosages are provided only for adults. Conclusions: The field of antimicrobial-resistance is highly dynamic. Consultation with an infectious diseases specialist is recommended for the treatment of antimicrobial resistant infections. This document is current as of 31 December 2022 and will be updated periodically. The most current version of this document, including date of publication, is available at www.idsociety.org/practice-guideline/amr-guidance/.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., Han, C., Bisignano, C., Rao, P., Wool, E., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02724-0 · Cited by 16,316
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449
Antibiotic resistance threats in the United States, 2019
(U.S.), C. F. D. C. A. P. (2019) · doi:10.15620/cdc:82532 · Cited by 5,782
Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O'Grady, N. P., Bartlett, J. G., Carratalà, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw353 · Cited by 3,892
Naghavi, M., Vollset, S. E., Ikuta, K. S., Swetschinski, L. R., Gray, A. P., Wool, E. E., Robles Aguilar, G., Mestrovic, T., Smith, G., Han, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01867-1 · Cited by 3,791
Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., Moran, G. J., Nicolle, L. E., Raz, R., Schaeffer, A. J., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq257 · Cited by 3,038
Updated Functional Classification of β-Lactamases
Bush, K., & Jacoby, G. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-09 · Cited by 2,367
Jacoby, G. A. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00036-08 · Cited by 2,165
Lister, P. D., Wolter, D. J., & Hanson, N. D. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00040-09 · Cited by 1,789
Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen
Brooke, J. S. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.00019-11 · Cited by 1,434
Research works printed but not linked: 10
- Clinical and Laboratory Standards Institute, 2023, M100: performance standards for antimicrobial susceptibility testing
- Sharara, 2019, Is piperacillin-tazobactam effective for the treatment of pyelonephritis caused by ESBL-producing organisms?, Clin Infect Dis, 71
- Centers for Disease Control and Prevention, 2015, Facility guidance for control of carbapenem-resistant Enterobacteriaceae (CRE): November 2015 update—CRE toolkit
- Chen, 2022, Efficacy and safety of ceftazidime-avibactam for the treatment of carbapenem-resistant enterobacterales bloodstream infection: a systematic review and meta-analysis, Microbiol Spectr, 10
- Shields, 2017, Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections, Antimicrob Agents Chemother, 61
- Li, 2022, Increased expression and amplification of blaKPC-2 contributes to resistance to ceftazidime/avibactam in a sequence type 11 carbapenem-resistant Klebsiella pneumoniae strain, Microbiol Spectr, 10
- Morrissey, 2020, In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017, Antimicrob Agents Chemother, 64
- Karlowsky, 2020, In vitro activity of imipenem/relebactam and ceftolozane/tazobactam against clinical isolates of gram-negative bacilli with difficult-to-treat resistance and multidrug-resistant phenotypes—SMART United States 2015–2017, Clin Infect Dis, 72
- Skoglund, 2018, In vivo resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa arising by AmpC- and non-AmpC-mediated pathways, Case Rep Infect Dis, 2018
- Cheah, 2015, New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection, J Antimicrob Chemother, 70, 3291
Cited by
Items 701–800 of 808
Jadhav, P. S., Mane, P. M., & Patil, S. (2026) · Cureus · doi:10.7759/cureus.109750
“These enzymes confer resistance to penicillins, first-through third-generation cephalosporins, and aztreonam, while maintaining variable activity against fourth-generation cephalosporins [41,5].”
Single Antibiotic Use With Ceftriaxone for Prophylaxis of All Open Fractures
Koulopoulos, M. W., Buseck, A., Lynch, C. P., Lutz, K. J., Brand, O., Sommers, E. J., Pompo, I., Laychur, A. J., Vaughn, J. E., Mann, K., et al. (2026) · Journal of Orthopaedic Trauma · doi:10.1097/bot.0000000000003229
Baker, K. A., Inala, S., Uzair, S., Haddad, M., & Thomas, S. (2026) · Cureus · doi:10.7759/cureus.109802
“Intravenous cefepime, which is stable against AmpC β -lactamases [9], was initiated based on susceptibility results.”
Yuan, W., Zhao, X., Liu, X., Tao, X., & Zeng, L. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1849617
“…however, the emergence of carbapenem-resistant P. aeruginosa poses a serious clinical challenge, and recent international guidelines recommend newer β -lactam/ β -lactamase inhibitor combinations such as ceftazidime–avibactam for selected resistant gram-negative infections (Tamma et al., 2024).”
Emeraud, C., Abad, L., Crolet, V., Santos, S. D., Noel, G., Rivat, S., Zambardi, G., & Dortet, L. (2026) · Journal of Clinical Microbiology · doi:10.1128/jcm.00222-26
Hu, Q., & Wang, H. (2026) · Infection and Drug Resistance · doi:10.2147/idr.s594482
Aziz, A. A., Goh, Q. L., Ismail, A. J., Zulbadrisham, N. H., Rajahram, G. S., & Jamil, N. S. F. M. (2026) · Asian Journal of Medicine & Health Sciences · doi:10.70672/ma5zcr76
Shetty, A., & Shankar, M. (2026) · World Journal of Nephrology · doi:10.5527/wjn.118797
Liao, S., & Shen, L. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1804539
Xu, A., Xiong, X., Zhang, N., Qu, G., Zhang, Z., & Cai, Y. (2026) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2026.107884
Chapter 36: Anti-Infective Agents
Hawkins, B. K. (2026) · doi:10.21019/9781582123875.ch36
Systematic Review of Intravenous Ceftriaxone Administration in Animals
de Vasconcelos, P. M. F., Rodrigues, G. D. B., & de Campos, M. L. (2026) · Veterinary Medicine and Science · doi:10.1002/vms3.71027
“…bacteria ( Escherichia coli , Proteus spp., Klebsiella spp., Enterobacter spp., Salmonella spp. and Pasteurella spp.) (Rodríguez-Baño et al. 2018 ; Tamma et al. 2023 ) and certain anaerobic bacteria ( Bacteroides fragilis , Peptostreptococcus spp., Clostridium spp.) (Ligero-López et al. 2023 ).”
Liu, J., Zhu, J. F., Liang, G., Yang, Y., Yu, L., Zhao, Y., & Yu, Z. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1838789
“Thus, many guidelines recommend therapeutic drug monitoring (TDM) of polymyxin B to reduce the risk of nephrotoxicity and maintain its efficacy (Tsuji et al., 2019; Abdul-Aziz et al., 2020; Liu et al., 2023; Tamma et al., 2023).”
Головка, М. І., & Holovka, M. I. (2026) · DSpace BSMU
Cohen, R., Dortet, L., Caséris, M., Raymond, J., Lorrot, M., & Toubiana, J. (2026) · Journal de Pédiatrie et de Puériculture · doi:10.1016/j.jpp.2026.06.004
Erdem, B., Yurtsever, G., Aras, M., Yılmaz, E., Yurttutan, A. E., Çalışkan, H. M., Ağgül, V., Şahin, İ., Varhan, Ö. E. D., İkiz, F., et al. (2026) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.4154
Cui, Y., Feng, X., Shao, R., Zhang, L., Li, X. F., Lin, Q., Wang, J., Liu, L., Pan, L., Zhen, S., et al. (2026) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-026-01790-z
“Guided by Infectious Diseases Society of America (IDSA) [33] and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) [34] recommendations, CRE BSIs prioritized ceftazidime-avibactam or polymyxin-based regimens.”
Rohatgi, D., & Moorjani, H. (2026) · Cureus · doi:10.7759/cureus.112449
Ngwu, T. A., Olasunkanmi, O. O., Akpe, V., & Cock, I. E. (2026) · Pharmacognosy Communications · doi:10.5530/pc.2026.3.16
Rajni, E., Galav, H., & Bairwa, K. (2026) · Journal of Research in Clinical Medicine · doi:10.34172/jrcm.026.34799
Relebactam enhances the activity of imipenem against Burkholderia cepacia complex isolates
Liang, L., Mane, J., Hilbert, D. W., Motyl, M. R., Lange, H. S., McKenney, D., Estabrook, M., DeRyke, C. A., Sahm, D. F., & Young, K. (2026) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2026.07.009
Marinova-Bulgaranova, T. V., Hristova, P., Marinovska, P., Balgaranov, N. K., Nankov, V. M., Peykov, S., & Hitkova, H. Y. (2026) · Microorganisms · doi:10.3390/microorganisms14081618
“Sulbactam–durlobactam combined with a carbapenem is now recommended as first-line therapy, whereas high-dose ampicillin–sulbactam represents an alternative combined with a second active agent such as polymyxin B, minocycline, tigecycline, or cefiderocol [65,66].”
Shopen, N., Margalit, Y., Thomas, R., Cohen, N., & Dekel, M. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04471-2
Multidrug resistant bacterial infection in liver transplant recipients: A Deterrent and obstacle
Arshad, N., Haider, J., Hassan, M., & Fatima, M. (2026) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.42.8.15347
Setu, S. K., Sattar, A. N. I., Firoz, M. T. H., & Taufiq, S. (2026) · Islami Bank Medical College Journal · doi:10.70945/ibmcj.v21i02.0220
Apostolidi, E. A., Basoulis, D., Zerva, S., Karapanou, Α., Pantazatou, A., Deliolanis, I., Markogiannakis, A., Sipsas, N. V., & Gamaletsou, M. N. (2026) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0000000000001630
Aka, S. T. H. (2026) · Iranian Journal of Microbiology · doi:10.18502/ijm.v18i4.22192
Yang, Y., Lv, J., Tian, J., Yu, S., Wang, G., & Ma, L. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1807363
Gavaruzzi, F., Madeddu, G., Ricci, E. D., Faltoni, M., Bandera, A., Colucci, F., VITO, A. D., Maccaro, A., Maggi, P., Piconi, S., et al. (2026) · Antibiotics · doi:10.3390/antibiotics15080796
“In this context, optimized infusion strategies may improve target attainment, limiting underexposure, and potentially reducing microbiological failure or emergence of resistance [5,6,9,10].”
InfluentialKhan, M., Patil, P. S., & Rathored, J. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1913726
“Consequently, treatment should be guided by antimicrobial susceptibility testing and local resistance epidemiology (Tamma et al., 2023).”
Kitano, T., Tsuzuki, S., & Yoshida, S. (2026) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlag175
de la Torre, J. C. G., Hueda-Zavaleta, M., Ríos, L. A., Valenzuela-Rodríguez, G., Rosa, A. M. L., & Polis, T. J. B. (2026) · PLoS ONE · doi:10.1371/journal.pone.0356004
Schneider, A., Cairns, K. A., van Gorp, E., Maćešić, N., Beiers, M., Vezina, B., Skeggs, J., Patwa, R., Parker, M., Doan, N. Q., et al. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00587-26
Arnautu, E. M., Pleșea, E. L., Zlatian, O. M., Camen, G. C., Mititelu, R. R., Osman, A., Țieranu, M.-L., Golli, A. L., & Ghenea, A. E. (2026) · Microorganisms · doi:10.3390/microorganisms14091908
Beer, M., SPENCER, J. M., & Mulholland, A. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.31.748333
Tong, D. M. H., Faldasz, J. D., Keizer, R. J., & Hughes, J. H. (2026) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70231
“1,2 Their antibacterial efficacy is concentration-dependent, and dosing strategies are designed to achieve high peak concentrations for efficacy while permitting sufficiently low concentrations between doses to limit toxicity.”
The influence of chlorogenic acid disinfection on the oral microbiota of alginate impressions
Cui, T., 胡美春, Jiang, S., Chen, F., Hu, Q., Yang, L., & Li, N. (2026) · Journal of Oral Microbiology · doi:10.1080/20002297.2026.2727218
“Pseudomonas is the second most prevalent Gram-negative bacterium associated with hospital-acquired infections, and it is a metabolically versatile environmental ‘survival expert’ that is dis tinguished by its robust biofilm-forming capacity and intrinsic drug resistance [42–44].”
Karolyi, M., Stahl, D., Naegeli, M., Pawelka, E., Zoufaly, A., & Wenisch, C. (2026) · Infection · doi:10.1007/s15010-026-02962-0
Phenazine Biosynthesis Inhibitors as Pseudomonas aeruginosa Antivirulence Agents
Handke, M., Baumgarten, J., Thiemann, M., Zimmermann, M., Empting, M., Dietrich, L. E. P., Kunick, C., Blankenfeldt, W., & Schiedel, M. (2026) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.6c00146
Chen, L., Yin, D., Hu, H., Kang, J., Rouzimaimaiti, R., Duan, J., & Hou, R. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1930952
Diverse transcriptomic effects of evolved imipenem-relebactam resistance in Pseudomonas aeruginosaPreprint
Supandy, A., Dorazio, A. J., Squires, K. M., Kline, E. G., Shields, R. K., & Tyne, D. V. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.12.751187
Mehmood, A., Zulfiqar, S., Khan, A., Hafeez, S., Shabbir, A., Zia, A., Mujahid, A. Y., & Naseem, T. (2026) · Genetics and Molecular Research · doi:10.4238/ggnk6s27
Hogea, E., Pilut, C. N., Bratosin, F., Rusnac, A.-N., Plavițu, O., Stanga, L., & Branea, H. S. (2026) · Microorganisms · doi:10.3390/microorganisms14092071
“…advantage over colistin-based regimens in carbapenem-resistant Enterobacterales bacteraemia in meta-analysis [37], and current guidance reserves distinct roles for sulbactam–durlobactam, ceftazidime–avibactam with aztreonam, and cefiderocol according to organism and resistance mechanism [38].”
Global epidemiology of carbapenem-resistant Pseudomonas aeruginosa
Gottesdiener, L. S., & Satlin, M. J. (2026) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlag208
Ologunowa, A. J., Caffrey, A. R., Cohen, S. A., & Kogut, S. J. (2026) · medRxiv · doi:10.64898/2026.09.13.26362951
Kefala, S., Fligou, F., Chandroulis, I., Amerali, M., Tsoupra, S., Zarkadi, E., Polyzou, E., Pnevmatikou, P., Kolonitsiou, F., & Akinosoglou, K. (2026) · Microorganisms · doi:10.3390/microorganisms14092098
Franceschi, G., Marchi, M., Cantergiani, S., Orlando, G., Casolari, S., Franceschini, E., Bedini, A., Mussini, C., & Meschiari, M. (2026) · Antibiotics · doi:10.3390/antibiotics15090935
Liu, J. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag601
Miguel, M. E. D., Lorenzo, L. B., Berenguer, A. S., de la Hoz, B. R., Arregui, M. G., Díaz, F. J. C., Díaz, P. R., Abad, M. J. G., Ascaso, M. T. G., & Vendrell, M. C. (2026) · European Journal of Pediatrics · doi:10.1007/s00431-026-07446-9
Potii, V. V., Zaytsev, I. A., Kiriienko, V. T., Melnyk, V., Potii, D. O., & Antoniuk, I. V. (2026) · Tuberculosis Lung Diseases HIV Infection · doi:10.30978/tb2026-3-88
Özçelik, M. N., & Erdem, İ. (2026) · Niğde Tıp Dergisi · doi:10.70846/nigdetip.1846073
Hsueh, Y.-C., Lin, C.-H., Liu, P.-H., & Lin, Y.-H. (2026) · Endocrine · doi:10.1007/s12020-026-04777-3
Shaik, N., Simgamsetty, S., Yarlagadda, P., Penmethsa, U., & Jothinathan, M. K. D. (2026) · Cureus · doi:10.7759/cureus.117062
“Culture-directed de-escalation accounted for 21.6% (402/1,858) post-implementation compared with 56.9% (858/1,507) at baseline (p 0.001), while appropriate continuation of empirical regimens without modification increased from 19.0% (287/1,507) to 25.3% (471/1,858) (p 0.001) [26,28].”
InfluentialKaraiskos, I., & Poulakou, G. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag615
Vodarici, M.-E., Cernat, R. C., Dumea, E., Ioniţă, O.-E., Vișan, N.-M., Dumitrescu, P. A., Constantin, R., Cambrea, A. M., Mita, G., Panculescu, F. G., et al. (2026) · Antibiotics · doi:10.3390/antibiotics15111080
Mohamed, S. E. R., & Ali, S. M. (2026) · Microorganisms · doi:10.3390/microorganisms14112468
Maraolo, A. E., Astorri, R., Cirillo, P., Granata, G., Emiliozzi, A., Tescione, M., Brigante, G., Cicalini, S., Petrosillo, N., Gentile, I., et al. (2026) · Microorganisms · doi:10.3390/microorganisms14102203
Fang, C., Zhou, Z., Li, J., Zhang, X., Xia, J., Liu, S., Zhao, Y., Xu, X., Shang, S., & Zhou, M. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.01719-26
Besi, A. P., Yasin, N. M., & Puspitasari, I. (2026) · Majalah Farmaseutik · doi:10.22146/farmaseutik.v22i3.102777
Alkhanafsa, M., Wafi, J., & Deek, S. M. S. (2026) · Infection · doi:10.1007/s15010-026-02991-9
Somchai, C. (2026) · Journal of Environmental Education Medical and Health
Ruan, B., Danjia, X., Yan, L., & Deng, N.-Y. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1856558
Shi, H., Zhou, Y., Wang, F., Tan, C., Yang, Z., Guo, C., Si, Z., & Zhang, J. (2026) · Chemical Communications · doi:10.1039/d6cc05091c
Vulpie, S., Ceachir, P., Craciun, A.-M., Varan, I., Izmendi, O., Dugăeșescu, D., Muntean, D., & Licker, M. (2026) · Antibiotics · doi:10.3390/antibiotics15100986
Gatti, M., Rinaldi, M., Ambretti, S., Giannella, M., Viale, P., & Pea, F. (2026) · Antibiotics · doi:10.3390/antibiotics15100990
Fang, Y., Gwiazdon, M., Chapin, R. W., McCoy, C. P., & Bell, K. (2026) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2026.10908
Pak, W. L. W., Yap, D. Y. H., Cheng, L. S., Chau, S. K., Lam, C. K., & Wong, S. H. S. (2026) · Peritoneal Dialysis International · doi:10.1177/08968608261493212
Global genomic epidemiology of multi-carbapenemase EnterobacteralesPreprint
Lerminiaux, N. A., Nagy, D., Lipworth, S., Shaw, L. P., Mataseje, L. F., Hopkins, K. L., Chau, K., & Stoesser, N. E. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.07.757280
“The major carbapenemase families (IMP, KPC, NDM, OXA-48-like, VIM) have varying hydrolytic profiles and inhibitor susceptibilities and therefore require different clinical treatment strategies 7 .”
Mohamed, F. A., Satti, A. A. E., Khalaf, H. S., & Fayed, A. A. (2026) · RSC Advances · doi:10.1039/d6ra06419a
Cefiderocol y Stenotrophomonas maltophilia: entre la evidencia preclínica y la incertidumbre clínica
Morante‐Ruiz, M., Matteo, A. B.-D., Rodríguez-Martín, G., & Cañavate-Sánchez, C. (2026) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2026.503316
Jimenez, L. M. R., Díaz, L., Quiroz, V. E., Martínez, J. R. W., Solar, C., Khan, A., Soto, K., Soto, P. R., Acuña, M.-P., Rioseco, M. L., et al. (2026) · Journal of Clinical Microbiology · doi:10.1128/jcm.00797-26
Self-citationTong, H., Mao, T., Zhu, G., 田欣欣, Qiao, Y., Guo, S., Deng, Y., & Li, X. (2026) · Analytica Chimica Acta · doi:10.1016/j.aca.2026.346381
Oral Fosfomycin for Complicated Urinary Tract Infection Remains a Murky Issue
Trautner, B. W., Cortes-Penfield, N. W., Gupta, K., Hirsch, E. B., & Lavergne, V. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag553
Villada, M. G. N., Restrepo, A., Trujillo-Valencia, M., Viana, A. M., Gómez, M. A., Padilla, L. M. R., & Díaz, A. (2026) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piag109
Koca, H., & Ayvat, P. U. (2026) · Infection · doi:10.1007/s15010-026-03019-y
Bucătaru, A., Osman, A., Zlatian, O. M., Arnautu, E. M., Bălăşoiu, A. T., Bălăşoiu, M., Camen, G. C., Sălan, A. I., Golli, A. L., & Ghenea, A. E. (2026) · Antibiotics · doi:10.3390/antibiotics15101027
“…for the early review of empirical therapy, since current guidance recommends agents such as ceftazidime–avibactam or meropenem–vaborbactam for infections caused by KPC-producing Enterobacterales [20], and meropenem–vaborbactam has also been evaluated in a randomized trial in this setting [21].”
Francisco, C., Tonga, A. D., Geganzo, S. G., Gantuangco, J. M., Poblete, J. B., Cruz, I. M., Santiago, B., Lee, J. S., Oyabu, T., Suzuki, M., et al. (2026) · IJID Regions · doi:10.1016/j.ijregi.2026.101039
Rocha, M. K. D. S., de Oliveira, N. S., Mattos, R. R., Paes, B. C., Gomes, I. R. G., Farias, L. C., Barbosa, A. C. F., Carvalho, C. V., Cavalcante, J. S., & Portela, F. V. M. (2026) · Brazilian Journal of Case Reports · doi:10.52600/2763-583x.bjcr.2026.6.1.bjcr232
Shabi, Y., Asiri, F. M. A., Binkhamis, K. M., Somily, A. M., Alshahrani, M. M., Al-Azraqi, T. A., Mohammed, S. A., Habbash, S., bshabshe, A. A. A. A., Mohamed, S., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0358963
“This pattern suggests that antibiotic class-specific non-susceptibility profiles, testing denominators, and clinical management practices may influence DTR dynamics beyond carbapenem non-susceptibility alone [11,21,23].”
InfluentialFirst Oral Carbapenem Comes to the United States, a Mixed Blessing
Pisciella, S., & Guerina, N. G. (2026) · Clinical Therapeutics · doi:10.1016/j.clinthera.2026.09.012
Alwashaish, M. M., Ashour, A. O., Elwash, M. E., & ELmeheishi, F. M. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.2002811
Şimşek, M., & Demir, C. (2026) · Microorganisms · doi:10.3390/microorganisms14102402
Vaz, S. D. S., Martins, L. B., Barbosa, L. C., REBELLO, N. A. C. C., dos Santos, A. L., Ferreira, D., Aires, C. A. M., Pellegrino, F. L. P. C., Zahner, V., de Mendonça-Souza, C. R. V., et al. (2026) · DNA · doi:10.3390/dna6040052
Panda, A., Haridas, H., Panda, P. S., Sahoo, B., & Nair, D. (2026) · Microbiology Independent Research Journal (MIR Journal) · doi:10.18527/20261326573
Stepaniuk, S. V., Prylypko, V. O., Obertynska, O. V., Ankin, M., Ladyka, V., Tertyshnyi, S. V., Zavertilenko, Y. S., & Kravets, D. T. (2026) · TRAUMA · doi:10.22141/1608-1706.5.27.2026.1110
Azarashk, A., Hashemian, S. M., & Saffaei, A. (2026) · International Journal of Infection · doi:10.5812/iji-174868
Sannathimmappa, M. B., Nambiar, V., Al-Maqbali, S., Parameshwarapppa, J., & Metri, B. C. (2026) · Scientific Journal of King Faisal University Basic and Applied Sciences · doi:10.1007/s44523-026-00015-7
Optimizing cefiderocol use in clinical practice
Sharara, S. L., Hsu, A. J., Simner, P. J., & Tamma, P. D. (2026) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000001243
Self-citationYessenbayeva, G. A., Mukatova, I. Y., Zholdybayeva, E. V., Merenkov, Y., Avakyan, Y., Berdiyarova, G. S., Shalekenov, S. B., Khudaibergenova, M. S., & Burkitbayev, Z. K. (2026) · medRxiv · doi:10.64898/2026.10.23.26366297
Rodríguez-Gómez, M., Braojos, F., Esteban, C. P., Carrillo, S. F., Serrano, M. S. A., López-Olivencia, M., de Burgos‐Lunar, C., Soriano, C., Candel, F. J., & Martínez‐Sagasti, F. (2026) · Antibiotics · doi:10.3390/antibiotics15111069
Gram-Negative Bacterial Resistance
Tamma, P. D. (2026) · New England Journal of Medicine · doi:10.1056/nejmra2506114
Self-citationGlover, J. S., Banerjee, R., & Abdul‐Mutakabbir, J. C. (2026) · Current Infectious Disease Reports · doi:10.1007/s11908-026-00894-2
Lopes, G. A. D. S., Prates, L. B., Jacometto, R. M. G. D. O., Palomo, C. T., & Ecker, A. B. S. (2026) · Aracê. · doi:10.56238/arev8n10-150
Wu, Z., Huang, L., Fu, L., Zou, C., Li, W., Yu, Y., Li, X., & Zhou, H. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106536
Aşık, A., Duyu, M., Erten, E. S. Y., Dündar, T., Pehlivan, P., & Özkavaklı, A. (2026) · Journal of Intensive Care Medicine · doi:10.1177/08850666261500074
Schmitz, L., Hamon, A., Coussement, J., Polo, J. M., Scemla, A., Laethem, J. V., & Lafaurie, M. (2026) · CMI Communications · doi:10.1016/j.cmicom.2026.105233
Lee, S., Jun, C.-H., Kim, H. T., Cho, H. K., Jung, J. W., Kim, S., & Wi, Y. M. (2026) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2026.103410
Eckmann, C., Akova, M., Antonelli, M. M., Bassetti, M., Cantón, R., Dryden, M., Falcone, M., Kanj, S. S., Kiertiburanakul, S., Gilchrist, M. J., et al. (2026) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlag226
Chen, P., Wang, X., Yi, Z., Liu, Y., Chen, Y., Shen, P., Ji, J., Ying, C., Liu, Z., & Xiao, Y. (2026) · Engineering Microbiology · doi:10.1016/j.engmic.2026.100315
Kuncka, A., Leśnik, P., Słabisz, N., Janc, J., Fangrat, M., Kołat-Brodecka, P., & Dzierżanowska‐Fangrat, K. (2026) · Pathogens · doi:10.3390/pathogens15111136
Metadata
- Authors
- Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J.
- Affiliations
- Johns Hopkins University (US)
- University of Michigan (US)
- University Hospitals of Cleveland (US)
- University of Virginia (US)
- Department of Medicine, University of North Carolina School of Medicine , Chapel Hill, North Carolina ,
- University of Pittsburgh (US)
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-07-18
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W4384665204
- Cited by
- 740
- References
- 697
- Citations by year
- 2026: 134 · 2025: 159 · 2024: 335 · 2023: 84
- FWCI
- 60.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- AstraZeneca
- Infectious Diseases Society of America
- Case Western Reserve University
- Medicines Company
- Melinta Therapeutics
- Entasis Therapeutics
- European Society of Clinical Microbiology and Infectious Diseases (ESCMID 2022)
- Universidade Federal do Rio Grande do Sul
- Shionogi
- Basilea Pharmaceutica
- Wockhardt
- National Institutes of Health
- Centers for Disease Control and Prevention
- Allergan
- Topics
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Microbiology (medical) › Infections and bacterial resistance
- Keywords
- antimicrobial resistance, gram-negative bacterial infection, extended-spectrum beta-lactamase, AmpC beta-lactamase, carbapenem-resistant Enterobacteriaceae, Pseudomonas aeruginosa, carbapenem-resistant Acinetobacter baumannii, Stenotrophomonas maltophilia, antimicrobial therapy, empirical treatment, oral therapy, treatment duration, pediatric infection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.